OP18 Shall We Pay More For Rare Disease Drugs? Assessing Decision-Makers’ Preferences Using A Sequential Discrete Choice Experiment Approach
Yuanyuan Gu, Shan Jiang, Shunping Li, Haiyin Wang · 2025
Read OP18 Shall We Pay More For Rare Disease Drugs? Assessing Decision-Makers’ Preferences Using A Sequential Discrete Choice Experiment Approach by Yuanyuan Gu, Shan Jiang, Shunping Li, Haiyin Wang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12768817.txt.
Description
Yuanyuan Gu, Shan Jiang, Shunping Li, and Haiyin Wang ask whether health decision makers in China would pay more for rare disease drugs in a 2025 study. Standard value measures based on years of healthy life may miss why rare disease care feels worth more. The team run two rounds of choice tasks with insurance decision makers.
Rarity alone added no value in the first round. What mattered most was how severe the disease was and how new the treatment was, along with its health gain. The second round implied a cost limit for rare diseases about three times the usual baseline. The authors link that premium to fairness concerns.
Catalog record
| CREATOR | Yuanyuan Gu, Shan Jiang, Shunping Li, Haiyin Wang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |